March 1, 2016

Dear Member of Parliament,

It is with great pleasure that Research Canada: An Alliance for Health Discovery and its Supporters and Partners welcome you for the first time, or welcome you back to Ottawa and Parliament Hill. Research Canada is a national organization whose Members, Supporters and Partners are dedicated to advancing health research and health innovation in Canada. Our Members, Supporters and Partners are hospital-based research institutes, universities, biopharma, biotechnology and medical device companies, health professional organizations and health charities.

Research Canada works closely with all political parties in every Parliament to organize a non-partisan Health Research Caucus. Chaired by the government of the day, with representation from opposition parties, the Caucus runs four to five receptions and luncheons a year that educate Parliamentarians about different areas of health research and health innovation. Examples include diabetes research, cardiovascular research and heart health, medical device technologies, brain and pain research, and vaccine development in Canada. This year we will organize several events including two receptions focused on Pediatric Research and Child Health and Frailty Among the Aged in Canada.

On March 7, 2016, the Minister of Health, the Honourable Jane Philpott, will host a Welcome Reception for Parliamentarians on Parliament Hill to announce the 42nd Parliament’s new Health Research Caucus and introduce Parliamentarians to dedicated leaders in the health research and health innovation fields.

This Welcome Kit is a resource developed by Research Canada for Parliamentarians to introduce you to the health research and health innovation communities and to highlight some of the excellence in health research and health innovation being carried out by Canadian health researchers and innovators in this country. As a country, we should be proud of our scientists and the discoveries they are making every day aimed at improving the health and quality of life of Canadians.

Russell Williams
President,
Innovative Medicines Canada
Canada’s life sciences industries are also making a difference in Canadian lives. Pharmacogenomics, for example, is the technology that analyses how genetic makeup affects an individual’s response to drugs. This biotechnology optimizes drug therapies and ensures maximum efficacy with minimal adverse effects for Canadian patients. The biopharma industry is developing new medicines and vaccines that save lives and help make our healthcare system more cost-effective. Medical device technologies help save the lives of patients in Canada by improving the accuracy of diagnoses, enhancing treatments and cures of diseases. Covering a wide range of products, medical device examples include pacemakers, artificial heart valves, hip implants and synthetic skin to name just a few.

On behalf of Research Canada’s Board, Members, Supporters and Partners, I look forward to working with you in our collective efforts to build a healthy and prosperous nation through investments in Canadian health research and progressive policies in support of Canada’s life sciences industries.

Sincerely,

Deborah Gordon-El-Bihbety
President and CEO,
Research Canada

---

**Providence Health Care Research Institute (PHCRI)** is an integrated healthcare research enterprise and the innovation and research arm of Providence Health Care, a non-profit, faith-based healthcare organization operating 16 sites across Greater Vancouver, BC. PHCRI brings world-class researchers and clinicians together to tackle some of the world’s most complex health problems, with focus on six populations of emphasis: HIV/AIDS, heart and lung health, kidney disease, urban health, mental health and addictions, and healthy aging. These areas of research directly inform patient treatment and care.

PHCRI continues to build on existing strengths to address new and ongoing complex and costly healthcare issues. We envision a renewed academic health science centre in the future that embodies a continuous learning and patient- and family-centered continuum of wellness and care. Evidence development and its application will be natural extensions of exceptional clinical care, along with organizational culture change to foster measurably improved health outcomes. Our patients and families will be key participants in our endeavours, and new knowledge will be captured as an integral by-product of each care experience. Informatics, knowledge translation and outcomes based incentives will drive a health ecosystem that will foster true innovation.
Canada is a nation of innovators. On a per capita basis, Canada boasts the fourth-largest science and technology workforce in the world\(^1\) —and nowhere is our heritage richer and our potential greater than in health research. As Chair of Research Canada, it is my great privilege and daunting responsibility to represent the wealth of talent that distinguishes Canada’s health research enterprise, and my greatest preoccupation is to ensure that, as a country, we continue to cultivate an asset that is so essential to the future of our healthcare system, to our economy and to the wellbeing of our population.

Canada’s health researchers are among the finest in the world. We have every reason to relish the milestones that have defined Canada’s contribution to health research—isolation of insulin, discovery of stem cells, decoding the building blocks of the immune system—but what gives us hope for the future is the enduring stature of Canadian researchers on the global stage. Based on 2014 data compiled by SCImago, Canada’s published health research is among the most impactful in the world, ranking among the top-5 countries in six of the eight health research categories SCImago tracks (and in the top-10 in all categories). And, propelled by targeted investments through CERC, CFREF and CFI, Canada has distinguished itself as a place where transformative research will continue to flourish in areas where Canada enjoys a competitive scientific advantage. We are a country of profound ideas and great science; we have the foundation to make a powerful contribution to human health and wellbeing.

<table>
<thead>
<tr>
<th>Global Impact Ranking (H-index)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicine</td>
</tr>
<tr>
<td>Psychology</td>
</tr>
<tr>
<td>Health Professions</td>
</tr>
<tr>
<td>Neuroscience</td>
</tr>
<tr>
<td>Nursing</td>
</tr>
<tr>
<td>Pharmacology, Toxicology &amp; Pharmaceuticals</td>
</tr>
<tr>
<td>Biochemistry, Genetics &amp; Molecular Biology</td>
</tr>
<tr>
<td>Immunology &amp; Microbiology</td>
</tr>
</tbody>
</table>

Source: SCImago Journal and Country Rank (www.scimagojr.com)

The Canadian Society for Molecular Biosciences (CSMB) represents thousands of the country’s leading biosciences faculty members and students. CSMB members work in the fields of biochemistry, cell biology, molecular biology and genetics on a diverse range of fundamental questions from understanding cell cycle control in single cells, genetic engineering of microbes and plants to produce drugs and high-value chemicals such as biofuels to development of innovate cures and diagnostics for diseases.

Professional activities of the Society include an annual meeting, sponsorship of symposia and student activities across Canada and celebrating the outstanding accomplishments of Canadian Molecular Bioscience researchers through a variety of awards, including lifetime and young research awards.

Our members’ research programs are largely dependent on operating funding from the Canadian Institutes of Health Research (CIHR) and the Natural Sciences and Engineering Research Council of Canada (NSERC). CSMB looks forward to working with the new government to help create a better model for discovery-based research, one that promotes the sustainable development of innovative research and invests in the training of the next generation of leaders that will contribute to the economic and knowledge wealth in Canada. To learn more about CSMB’s initiatives, visit csmb-scmb.ca

---

At AstraZeneca, our purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve this is to put science at the centre of everything we do. As part of that commitment, AstraZeneca Canada is proud to sponsor Research Canada’s Welcome Reception for Members of Parliament. Congratulations on your election and welcome to Ottawa!

Lisa Marsden
Vice-President, Patient Access & Established Brands, AstraZeneca Canada

As a global leader in medical technology, services and solutions, Medtronic helps to improve the health and lives of millions of people each year. We believe our deep clinical, therapeutic and economic expertise can help address the complex challenges—such as rising costs, aging populations, and the burden of chronic disease—faced by families and healthcare systems today. But, we can’t do it alone. That’s why we’re committed to partnering in new ways and developing alternative solutions that deliver better patient outcomes.

Founded in 1949 as a medical repair company, we’re now among the world’s largest medical technology, services and solutions companies, employing more than 85,000 people worldwide, serving physicians, hospitals and patients in more than 160 countries.

With a presence since 1968, we are proud to employ over 1,500 people in Canada. Join us in our commitment to take healthcare further, together. Learn more at Medtronic.ca.
Canada’s healthcare system needs innovation. Notwithstanding the place of reverence healthcare occupies within our national consciousness—and despite the exceptional pool of healthcare innovators who call Canada home—Canada’s healthcare system is objectively underperforming. The Commonwealth Fund’s most recent analysis of eleven major healthcare systems ranks Canada 10th—just ahead of the US—in an aggregate measure of quality, access, efficiency, equity and outcomes. And the challenge isn’t how much we’re spending; it’s how we’re spending the resources we have. As the fifth most expensive healthcare system among comparator countries, Canada is a global laggard when it comes to integrating innovations in health practice, policy and technology. We are failing to capitalize on our exceptional research talent to invent, translate, develop and implement tomorrow’s healthcare.

Canada is falling behind as a funder of health research. Canada’s flagging healthcare reputation is not necessarily surprising. Among industrialized countries, Canada’s per capita investment in health research is the lowest in the world—and, in absolute dollars, our total investment is now less than that of Australia, a country two-thirds our size by population. No enterprise can compete and thrive without sustained investment in innovation; our healthcare system is no exception.

Research Canada’s message to policymakers is simple: let our health research and innovation talent—academic, clinical, industrial—create, experiment, fail and triumph. To this end, we need predictable, patient and generous investment in science; a policy environment that rewards risk-taking, entrepreneurship and investment in health innovation; and a healthcare system that is a receptive partner in piloting, procuring and establishing the environment for innovation. We owe it to ourselves—and, most importantly, to future generations—to invest in a health innovation system that harnesses Canada’s formidable health research talent, optimizes scarce healthcare resources, creates economic opportunity and improves the health of all Canadians.

Dr. Ryan Wiley
Chair, Research Canada
(President, Shift Health)

Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We help our members discover, develop, and deliver innovative medicines and vaccines. Our membership consists of more than 50 companies, from established organizations to fledgling startups, all of whom are revolutionizing healthcare through the discovery and development of new medicines and vaccines.

Guided by a strict Code of Ethical Practices, we work with governments, insurance companies, healthcare professionals and stakeholders to advance the field and enhance the wellbeing of Canadians. We are committed to being valued partners in Canada’s healthcare system. We aim to achieve these goals by forming effective alliances and supporting policies, improving Canada’s regulatory environment to widen access to innovative medicines and protect intellectual property.

We believe in ensuring that Canadians have access to the innovative treatments they need and that our activities are a fundamental part of safeguarding our healthcare system for future generations. Our work allows our members to focus on what matters: delivering better healthcare solutions to Canadians.
Welcome Kit

Established in 1958, The Michener Institute of Education at UHN is Canada’s only post-secondary institution devoted exclusively to health sciences education. Michener offers full-time and continuing education in Imaging, Medical Laboratory Sciences, Medical Radiation Sciences, Primary and Critical Care and other specialized applied health programs. With a robust and responsive curriculum that emphasizes inter-professional collaboration and simulation-based training, graduates are prepared to deliver quality diagnostic and therapeutic services.

Michener is publicly funded by the Ontario Ministry of Health and Long-Term Care and further enriched through partnerships with universities, private sector companies and leading healthcare organizations. Our curriculum is driven by the emerging needs of the healthcare system, so Michener faculty and students value and participate in research that informs the best patient outcomes.

Michener’s recent integration with University Health Network—Canada’s largest academic hospital—has further solidified the critical role health research plays in preparing the health labour force of tomorrow. It also accelerates the transfer of academic research at Michener from the school labs into clinical practice, benefiting students and healthcare professionals … and most importantly, the patient. For more information, visit www.michener.ca.

The possibilities for advancements in medical technology that are enabling new and better ways of providing care are endless. Over the next decade, I’m particularly excited to see new innovations that are increasingly enabling opportunities for care to be shifted out of hospitals and into patients’ homes. Not only is this smarter care, but it plays an important role in increasing the sustainability of our healthcare system as well.

Brian Lewis
President and CEO,
MEDEC

At Merck, we firmly believe that the process of improving patient care begins with research. Our company has pushed the boundaries of science since its foundation 125 years ago, with the hope and expectation that advances in scientific knowledge will lead to improved healthcare. Today, we are at the forefront of developing medicines and vaccines for the prevention and treatment of some of the most urgent global health challenges, including more than 30 different cancers, hepatitis C, Alzheimer’s disease, Ebola, antibiotic-resistant “superbugs,” and cardio-metabolic diseases. In Canada, Merck has a unique collaborative research model and actively supports the life science industry’s efforts to accelerate research and innovation. We look forward to the successful continuation of these partnerships.

Chirfi Guindo
President and Managing Director,
Merck Canada Inc.

AbbVie is pleased to partner with Research Canada in support of its work with the Health Research Caucus. Much work remains to be done to ensure Canada is at the forefront in the development of new medicines, and in ensuring these innovations are delivered to Canadians who need them. We support Research Canada’s vision of a robust Canadian life sciences research and development sector, and at AbbVie, are particularly pleased to partner with research institutions and governments to support a strong health research ecosystem, as well as innovative models of care, across the country.

Chirfi Guindo
President and Managing Director,
Merck Canada Inc.

At Merck, we firmly believe that the process of improving patient care begins with research. Our company has pushed the boundaries of science since its foundation 125 years ago, with the hope and expectation that advances in scientific knowledge will lead to improved healthcare. Today, we are at the forefront of developing medicines and vaccines for the prevention and treatment of some of the most urgent global health challenges, including more than 30 different cancers, hepatitis C, Alzheimer’s disease, Ebola, antibiotic-resistant “superbugs,” and cardio-metabolic diseases. In Canada, Merck has a unique collaborative research model and actively supports the life science industry’s efforts to accelerate research and innovation. We look forward to the successful continuation of these partnerships.

Chirfi Guindo
President and Managing Director,
Merck Canada Inc.

AbbVie is pleased to partner with Research Canada in support of its work with the Health Research Caucus. Much work remains to be done to ensure Canada is at the forefront in the development of new medicines, and in ensuring these innovations are delivered to Canadians who need them. We support Research Canada’s vision of a robust Canadian life sciences research and development sector, and at AbbVie, are particularly pleased to partner with research institutions and governments to support a strong health research ecosystem, as well as innovative models of care, across the country.

Chirfi Guindo
President and Managing Director,
Merck Canada Inc.

AbbVie is pleased to partner with Research Canada in support of its work with the Health Research Caucus. Much work remains to be done to ensure Canada is at the forefront in the development of new medicines, and in ensuring these innovations are delivered to Canadians who need them. We support Research Canada’s vision of a robust Canadian life sciences research and development sector, and at AbbVie, are particularly pleased to partner with research institutions and governments to support a strong health research ecosystem, as well as innovative models of care, across the country.

Chirfi Guindo
President and Managing Director,
Merck Canada Inc.
Health Research in Canada: Nation-Building in the 21st Century

Canada’s journey to nationhood has been a gradual, evolutionary process, a triumph of compassion, collaboration and accommodation, and the result of many steps, both simple and bold. This year we celebrate the 40th anniversary of medicare in Saskatchewan, a courageous initiative by visionary men and women that changed us as a nation and cemented our role as one of the world’s compassionate societies. The next big step for Canada may be more focused, but it will be no less bold. That next step is to build on this proud legacy and transform medicare into a system that is more responsive, comprehensive and accountable to all Canadians.

Romanow Commission on the Future of Health Care in Canada; 2002

The intersection between nationalism and government policy in Canada is well-documented. From infrastructure projects like the Trans-Canada Railway in the late 1800s to social welfare policies of the 1900s like unemployment insurance, and family and pension benefits, governments in Canada have helped to build our national identity through policies, programs and projects that have come to shape our national priorities and values.

Nothing has been more important to Canada’s nation-building, and our collective identity, than health policy. Since the 1960s, Canada’s publicly-funded healthcare system has become a key part of our national identity. For many Canadians, our healthcare system, and the values it is based on, differentiates and elevates Canada to its status as one of the greatest countries in the world. As Roy Romanow said in his report in 2002, “Canadians perceive health care as a national endeavour.”

As important as building our healthcare system was in the last century, Canada must set a new nation-building goal in the area of health policy. In the 21st century, having built one of the most-envied healthcare systems in the world, Canada must shift its focus and build a world-leading health research “system.” A renewed commitment to health research...
Welcome Kit

There are more than 400,000 Canadians living with long-term disability from stroke, and we feel we are on the cusp of game-changing discoveries. Investment in stroke recovery research is critical to restoring lives affected by stroke.

Dr. Dale Corbett
Scientific Director and CEO,
Heart and Stroke Foundation, Canadian Partnership for Stroke Recovery
Professor, Neurosciences,
University of Ottawa

As one of the world’s largest healthcare companies, we appreciate the important role the Federal Government plays in helping Canadians receive quality healthcare. We look forward to partnering with the newly elected Government to solve some of Canada’s biggest healthcare challenges. Innovative technologies, services and solutions will play a key role in transforming healthcare and we are excited to do our part to assist the Government, providers and patients in making Canada’s healthcare system the best in the world. Let’s take healthcare further, together.

Neil Fraser
President,
Medtronic

Health care is becoming increasingly complex as populations change, treatment landscape shifts, and the patient voice grows in its desire to be heard. The Providence Health Care Research Institute facilitates partnerships between all affiliated investigators to improve specific treatment areas and populations in British Columbia and to advance health care and the general scientific body of knowledge across Canada, while maintaining focus on the patient. A variety of initiatives and policies that account for the needs of an aging population and diverse treatment groups are needed to improve health care and health systems for all Canadians.

Dr. Aslam Anis
Director, Centre for Health Evaluation and Outcome Sciences,
Providence Health Care Research Institute

For more than 40 years, MEDEC, as the association representing Canada’s medical technology companies, has been working in partnership with governments, healthcare providers and patients to contribute to better health and more sustainable health care for Canadians.

MEDEC members are creating implantable devices, surgical tools, diagnostic technologies and many more innovations that are improving the lives of patients in Canada and around the world every day. These technologies are leading to earlier and more accurate diagnoses, less invasive procedures (meaning faster recoveries and reduced hospital stays), improved treatment options and reduced wait times to name just a few of the benefits. In addition to improving health outcomes, these technologies bring great value—making important contributions to ensure the sustainability of Canada’s healthcare system.

Through the ongoing research and development of innovative products, Canada’s medical technology industry contributes significantly to the effectiveness and efficiency of the healthcare system and to the wellbeing of Canadians, while helping to drive a vitally important sector of our economy—providing well-paying jobs to over 35,000 Canadians.
in Canada will unify the country in common purpose and pride, drive our knowledge economy and provide real and lasting health and societal benefits, as past social policies have in Canada.

Why Health Research?
Our health system has always been a source of national pride for Canadians. However, that system increasingly relies on new treatments and innovations to meet the emerging needs of our population. In many instances, and increasingly in the years to come, health research can help our system to create and adopt those needed treatments and innovations, and can be the focus of our nation-building and renewed pride for Canadians in the 21st century.

Health research is already tackling some of this country’s greatest health and health system challenges. Health research provides us with the evidence we require to decrease waiting times and provide better access to diagnostic services and treatment. We cannot improve our health system without the knowledge we acquire from research that allows us to make informed decisions about procedures and innovative system strategies. This evidence can only come from research that is rigorous, integrated and based on fact. Research helps to ensure a health system that is adaptable, responsive, innovative, cost-effective and accountable.

Health research also provides the means to test the effectiveness of new treatments, first in controlled environments, through clinical trials, then in actual use, through ongoing surveillance. It also helps to prevent disease by teaching us more about the factors that increase the probability of illness and our susceptibility to disease.

The economic impact of health research should also not be underestimated. Investments in health research accelerate our nation’s transition from largely a commodity/service-based economy to a knowledge-based economy, and in turn improve our nation’s global competitiveness, which is an economic imperative for Canada. More specifically, investment in health research:

- Provides the foundation for spin-off companies that supply important health services and products to Canadians while generating economic growth and creating jobs
- Fosters partnerships with the private and voluntary sectors that are leveraging the federal

The Canadian Association for Neuroscience (CAN) is a not-for-profit organization dedicated to the promotion of neuroscience research and the interests of Canadian Neuroscientists. We are an association of approximately 1000 independent researchers, professors and trainees actively involved in neuroscience research. CAN-ACN organizes the Canadian Neuroscience Meeting yearly since 2007. Our next meeting will be held in Toronto, May 29 - June 1 2016. We maintain an active website, at can-acn.org, which we use to showcase neuroscience research, to provide important information for our members about meetings, scientific and social events, funding opportunities, and employment offers, and to promote neuroscience advocacy initiatives.

As stated in our bylaws, our mission is to: 1) Promote communication among neuroscientists throughout Canada; 2) Represent the interests of Canadian neuroscientists at national and international levels; 3) Promote research in all disciplines contributing to the understanding of the nervous system; 4) Contribute to the advancement of education in the Neurosciences; 5) Provide for and assist in the dissemination to the general public of the results of current Neuroscience research and its significance in relation to health and disease; and 6) Raise funds and to provide income for the above purposes.
Research plays a critical role in every aspect of the healthcare spectrum, including how we prepare the healthcare labour force to adapt to scientific and systemic change. And as research continues to push evolution in medical science, education in schools and in hospitals needs to stay in step. Having a solid research foundation for our healthcare system helps the Michener Institute of Education at UHN constantly adapt curriculum to advances in health technology, ensuring new practitioners are ahead of the curve and anticipating changes.

Dr. Peter Pisters
President and CEO,
The Michener Institute of Education at UHN

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of primary and specialty care medicines that transform lives. Our primary focus is on three important areas of healthcare: Cardiovascular and Metabolic disease; Oncology; and Respiratory, Inflammation and Autoimmunity.

AstraZeneca operates in more than 100 countries and its innovative medicines are used by millions of patients worldwide. In Canada, we employ roughly 690 employees across the country and our AstraZeneca Canada headquarters are located in Mississauga, Ontario.

For more information, please visit the company’s website at www.astrazeneca.ca.
investment, integrating all partners into the development and implementation of strategic agendas for health research and maximizing the impact of health research dollars

• Provides Canada with skilled graduates who are equipped with advanced levels of training, knowledge and expertise
• Repatriates Canadian researchers from abroad and attracts distinguished foreign researchers to Canada, where their discoveries will benefit Canadians
• Creates a brighter future for Canada’s youth by providing opportunities to harness their energy and creativity in becoming the next generation of health researchers

Health Research: A National Priority

It should be no surprise that there is overwhelming support for health research in Canada. The benefits of health research are the priorities of Canadians: improved health, an efficient and sustainable health system and a prosperous economy that creates jobs.

In January 2015, Research Canada, in partnership with five national organizations and two provincial organizations, conducted a national public opinion poll on Canadians’ views of health research, health care and health innovation. The overall message of the poll was that, despite changes in our economy over the last decade, Canadians have not wavered in their commitment to the importance of supporting health and medical research because they recognize the benefits it can bring to our health and to our economy. A very strong majority of Canadians (90%) say that health research makes an important contribution to health care while a strong majority (77%) say it makes an important contribution to the economy.

Opportunity for Canada

While no one single policy measure will ensure Canada’s productivity performance and its capacity to innovate in the future, investing in the health of our citizens is the single most important decision we can make as a country to both increase the well-being of Canadians and to build a robust innovation nation. Growing our economy will be dependent upon a healthy and well-trained Canadian workforce generating innovations that give this country a competitive advantage in the global economy. Health research holds the key to improved health and quality of life for Canadians and can truly be a 21st century nation-building project for Canada.

Michelle McLean
Vice-President and Group Leader,
Public & Corporate Affairs,
Hill+Knowlton Canada

Today’s Merck is working to help the world be well. Merck is a global healthcare leader with a diversified portfolio of prescription medicines, vaccines and animal health products. In Canada, Merck markets more than 250 pharmaceutical and animal health products. Merck is a leader in a broad range of areas such as cardiology, infectious diseases, respiratory, vaccines and women’s health, and is focused on expanding offerings in other areas, including virology, oncology and diabetes.

Based in Montréal, Québec, Merck employs approximately 775 people across Canada. Merck is one of the top R&D investors in Canada, with investments totalling $22.6 million in 2013 and more than $1 billion since 2000. For more information about our operations in Canada, visit www.merck.ca and connect with us on YouTube.
Discovery research is at the heart of every advancement in biotechnology and medicine, from biofuels to cancer treatments to disease prevention. With a renewed focus on investing in growth and innovation in Canada, we look forward to working with the new government to restore sustainable support for fundamental research, and the next generation of leaders that will fuel a science, technology and innovation-inspired economy. It’s this kind of support that will not only improve the health of Canadians, but also stimulate the economy through the creation of new businesses and jobs.

Dr. Kristin Baetz
President,
Canadian Society for Molecular Biosciences

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.